文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

AMBITION试验:高剂量AmBisome治疗撒哈拉以南非洲隐球菌性脑膜炎的III期随机对照非劣效性研究方案

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
PubMed 文献 · Trials · 2018-11-23

本研究为在撒哈拉以南非洲五国开展的开放标签III期随机对照非劣效性试验,旨在比较单次高剂量脂质体两性霉素B联合高剂量氟康唑和氟胞嘧啶与七天两性霉素B脱氧胆酸盐联合氟胞嘧啶方案。主要终点为十周全因死亡率,非劣效界值10%,计划纳入850例HIV相关隐球菌性脑膜炎首次发作患者。

要点

  • 单次高剂量脂质体两性霉素B联合氟康唑和氟胞嘧啶可能简化隐球菌性脑膜炎诱导治疗。
  • 试验以十周全因死亡率为主要终点,非劣效界值设为10%。
  • 若达到非劣效,该方案可能减少两性霉素B脱氧胆酸盐相关不良事件并缩短住院时间。

核心结论

  • 单次高剂量脂质体两性霉素B联合高剂量氟康唑和氟胞嘧啶方案若被证实非劣于七天两性霉素B脱氧胆酸盐联合氟胞嘧啶方案,可能提供更安全、可持续且易于实施的替代方案。

研究设计与样本

  • 开放标签III期随机对照非劣效性试验,在博茨瓦纳、马拉维、南非、乌干达和津巴布韦五个撒哈拉以南非洲国家开展。
  • 计划纳入850例年龄≥18岁、首次发作HIV相关隐球菌性脑膜炎的患者,随机分配至两个治疗组各425例,随访16周。

主要发现

  • 原文未报告试验结果。

关键数值与推荐

  • 主要终点为十周全因死亡率,非劣效界值为10%,把握度为90%。
  • 试验组方案:单次10 mg/kg脂质体两性霉素B,联合14天氟康唑1200 mg/天和氟胞嘧啶100 mg/kg/天。
  • 对照组方案:两性霉素B脱氧胆酸盐1 mg/kg/天用7天,联合氟胞嘧啶100 mg/kg/天用7天,随后氟康唑1200 mg/天用7天。
  • 次要终点包括早期杀菌活性、III/IV级不良事件比例、药代动力学参数及药效学关联、卫生服务成本、第2周和第4周全因死亡率和十周内全因死亡率(优效性分析)、隐球菌性脑膜炎复发率、免疫重建炎症综合征发生率和十周残疾率。
  • 所有患者均接受氟康唑800 mg/天巩固治疗至总疗程十周,随后按当地指南进行氟康唑维持治疗和抗逆转录病毒治疗。

临床怎么用

  • 若该方案被证实非劣效,单次高剂量脂质体两性霉素B联合方案可能减少两性霉素B脱氧胆酸盐相关不良事件并缩短住院时间。
  • 该方案可能为当前WHO推荐的一线治疗提供高度可实施且可持续的替代选择。

局限性

  • 原文未报告试验结果,尚不能评价疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cryptococcal meningitis (CM) is a major cause of mortality in HIV programmes in Africa despite increasing access to antiretroviral therapy (ART). Mortality is driven in part by limited availability of amphotericin-based treatment, drug-induced toxicities of amphotericin B deoxycholate and prolonged hospital admissions. A single, high-dose of liposomal amphotericin (L-AmB, Ambisome) on a fluconazole backbone has been reported as non-inferior to 14 days of standard dose L-AmB in reducing fungal burden. This trial examines whether single, high-dose L-AmB given with high-dose fluconazole and flucytosine is non-inferior to a seven-day course of amphotericin B deoxycholate plus flucytosine (the current World Health Organization [WHO] recommended treatment regimen). METHODS: An open-label phase III randomised controlled non-inferiority trial conducted in five countries in sub-Saharan Africa: Botswana, Malawi, South Africa, Uganda and Zimbabwe. The trial will compare CM induction therapy with (1) a single dose (10 mg/kg) of L-AmB given with 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/day) to (2) seven days amphotericin B deoxycholate (1 mg/kg/day) given alongside seven days of flucytosine (100 mg/kg/day) followed by seven days of fluconazole (1200 mg/day). The primary endpoint is all-cause mortality at ten weeks with a non-inferiority margin of 10% and 90% power. Secondary endpoints are early fungicidal activity, proportion of grade III/IV adverse events, pharmacokinetic parameters and pharmacokinetic/pharmacodynamic associations, health service costs, all-cause mortality within the first two and four weeks, all-cause mortality within the first ten weeks (superiority analysis) and rates of CM relapse, immune reconstitution inflammatory syndrome and disability at ten weeks. A total of 850 patients aged ≥ 18 years with a first episode of HIV-associated CM will be enrolled (425 randomised to each arm). All patients will be followed for 16 weeks. All patients will receive consolidation therapy with fluconazole 800 mg/day to complete ten weeks of treatment, followed by fluconazole maintenance and ART as per local guidance. DISCUSSION: A safe, sustainable and easy to administer regimen of L-AmB that is non-inferior to seven days of daily amphotericin B deoxycholate therapy may reduce the number of adverse events seen in patients treated with amphotericin B deoxycholate and shorten hospital admissions, providing a highly favourable and implementable alternative to the current WHO recommended first-line treatment. TRIAL REGISTRATION: ISRCTN, ISRCTN72509687 . Registered on 13 July 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lawrence DS, Youssouf N, Molloy SF, et al. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. Trials. 2018. PMID: 30470259. doi:10.1186/s13063-018-3026-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。